FINWIRES · TerminalLIVE
FINWIRES

Sun Pharma Gets Brazil Approval for Semaglutide Injection

By

Sun Pharmaceutical Industries (NSE:SUNPHARMA, BOM:524715) has received approval from Brazil's health regulator, ANVISA, to manufacture and market semaglutide injection for adults with inadequately controlled type 2 diabetes, according to a Wednesday filing on Indian bourses.

The company plans to launch the product in Brazil in the coming days through a partnership with Hypera Pharma. The treatment will be available as a pre-filled, multi-dose injectable pen in two strengths with once-weekly dosing.

Shares of the pharmaceutical company rose nearly 1% in morning trade on Thursday.

Related Articles